Nochaiwong S, Chuamanochan M, Ruengorn C, et al. - According to the findings of this meta-analysis, the biologic agents ligelizumab (72 or 240 mg) and omalizumab (300 or 600 mg) can be recommended as effective treatments for patients with chronic spontaneous urticaria (CSU) who have not responded to H ₁ antihistamines.

• There were 23 randomized clinical trials with a total of 2,480 participants that compared 18 different interventions or dosages and placebo.

• It was noted that the standardized mean differences for change in urticaria symptoms were −1.05 for ligelizumab, 72 mg; −1.07 for ligelizumab, 240 mg; −0.77 for omalizumab, 300 mg; and −0.59 for omalizumab, 600 mg. There were no significant differences in treatment unacceptability. In terms of benefits and harms, network estimates revealed that the most effective treatments were ligelizumab, 72 or 240 mg (large beneficial effect) and omalizumab, 300 or 600 mg (moderate beneficial effect).